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The analysis of HIV-1 envelope carbohydrates is critical to understanding their roles in HIV-1 transmission
as well as in binding of envelope to HIV-1 antibodies. However, direct analysis of protein glycosylation by
glycopeptide-based mass mapping approaches involves structural simplification of proteins with the use of a
protease followed by an isolation and/or enrichment step before mass analysis. The successful completion of
glycosylation analysis is still a major analytical challenge due to the complexity of samples, wide dynamic range
of glycopeptide concentrations, and glycosylation heterogeneity. Here, we use a novel experimental workflow
that includes an up-front complete or partial enzymatic deglycosylation step before trypsin digestion to
characterize the glycosylation patterns and maximize the glycosylation coverage of two recombinant HIV-1
transmitted/founder envelope oligomers derived from clade B and C viruses isolated from acute infection and
expressed in 293T cells. Our results show that both transmitted/founder Envs had similar degrees of glyco-
sylation site occupancy as well as similar glycan profiles. Compared to 293T-derived recombinant Envs from
viruses isolated from chronic HIV-1, transmitted/founder Envs displayed marked differences in their glycosyl-
ation site occupancies and in their amounts of complex glycans. Our analysis reveals that the glycosylation
patterns of transmitted/founder Envs from two different clades (B and C) are more similar to each other than
they are to the glycosylation patterns of chronic HIV-1 Envs derived from their own clades.
The systematic mapping and characterization of protein gly-
cosylation provide a wealth of molecular information that is
crucial for understanding a wide variety of biochemical and
cellular processes. However, comprehensive analysis of protein
glycosylation has proven to be difficult due to the wide dynamic
range of glycopeptide concentrations and immense structural
diversity of glycans. Glycan modifications on proteins undergo
a series of glycan processing steps from the endoplasmic retic-
ulum (ER) to the Golgi apparatus with a diverse array of
glycan processing enzymes that compete for available sub-
strate, resulting in multiple glycosylation patterns for each
glycosylation site for a given protein and variation in glycosyl-
ation site occupancy (35, 52, 53). Moreover, protein glycosyl-
ation varies significantly across different cell types, cell states,
tissues, and organisms (3, 12, 16, 34, 35, 53, 56, 62). Despite
these challenges, recent advances in proteomics have acceler-
ated the pace of the development of efficient methods and
technologies that can be tailored for the analysis of protein
glycosylation (6, 51, 66). To date, the analysis of protein gly-
cosylation by mass spectrometry (MS) is underpinned by an
array of sample preparation methods that include affinity/en-
richment schemes (6, 18, 26), modern chromatographic meth-
ods (31, 50, 54), and remarkable improvements in mass spec-
trometry instrumentation (47, 48, 51). When used effectively,
these methods provide a means to qualitatively and quantita-
tively profile the global glycosylation of a given glycoprotein
sample.
An essential requirement to globally profile protein glycosy-
lation and maximize the information content of a given glyco-
sylation site is the characterization of glycosylation in a site-
specific fashion. A typical analysis employs a bottom-up
proteomics approach wherein glycoproteins are enzymatically
digested using a specific or nonspecific protease to generate
the peptide/glycopeptide mixture that is subsequently analyzed
by a mass spectrometry (MS) platform in tandem with the
chromatographic separation of choice (2, 11, 14, 18, 29, 48, 51,
66). Following data acquisition, all possible glycopeptides are
identified by peaks that are separated by monosaccharide units
and/or by peaks of characteristic glycopeptide-marker ions in
the MS1 and tandem-MS (MS/MS) data (9, 21, 66). The data
sets that are generated are then analyzed with downstream
software tools to deduce the glycopeptide compositions,
thereby elucidating glycosylation site occupancy and the glycan
motif at a given glycosylation site.
While this approach has proven to be useful, the high com-
plexity of glycoprotein samples imposes restrictions on the
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detection sensitivity of glycopeptides. Aside from having low
ionization efficiency compared to coeluting peptides, ioniza-
tion of glycopeptides is also obscured by ion suppression effects
and competition for ionization with coeluting glycopeptides in
complex biological milieu (11, 68). As a result, glycopeptides
that are present in relatively low abundance are detected with
reduced sensitivity or may be not detected at all. Herein, we
demonstrate an alternative approach to achieve a more com-
prehensive glycopeptide profile involving the use of glycosi-
dases, wherein glycopeptides are partially or completely degly-
cosylated prior to mass analysis. This approach affords the
benefits of accurate identification of glycosylation site occu-
pancy and the identification of the type of glycan populating a
particular site, and it facilitates the characterization of glyco-
peptides that poorly ionize in a given elution window or are not
detected at all when other glycopeptides are present, thus
maximizing glycosylation coverage. We have used this technol-
ogy to perform glycosylation site occupancy analysis and gly-
copeptide profiling of proteins of great biological interest—
recombinant HIV-1 Env oligomers derived from transmitted/
founder viruses.
A single transmitted/founder virus quasispecies has been
found to be involved in 70 to 80% of heterosexually transmit-
ted infections, but the characteristics of transmitted/founder
HIV-1 strains that permit transmission are not known (8, 13,
32, 58). The types of glycans on recombinant viral Env are
beginning to be characterized (5, 34), and the carbohydrates on
recombinantly expressed envelopes may not be fully represen-
tative of those glycans on virion Env spikes (15). Nonetheless,
comparison of recombinant transmitted/founder and chronic
HIV-1 Env glycosylation with new carbohydrate analysis tech-
nology is an important initial analysis, primarily because of the
anticipated use of recombinant transmitted/founder Envs in
human immunogenicity trials. The RV144 Thai HIV-1 vaccine
efficacy trial used a canarypox virus expressing envelope as a
vector prime followed by a bivalent Env gp120 protein boost
(57), and new efficacy trials will almost certainly also contain
Env protein boosts. Moreover, transmitted/founder viruses dif-
fer from chronic viruses in their biological functions, including
infectivity of macrophages (58), and in their ability to bind to
the integrin homing receptor 47 (49). In particular, the
ability of recombinant transmitted/founder Envs to bind to
47 while chronic Envs bind less well may in part be due to
their glycan profile (49).
If, when using new technology, site-specific carbohydrates
vary between transmitted/founder and chronic Envs, then it
will additionally warrant the even more difficult studies of
site-specific carbohydrates of transmitted/founder and chronic
virion trimers on CD4 T-cell-derived virions, to determine if
Env carbohydrates contribute to transmitted/founder virus suc-
cess in establishing the initial productive infection.
In the present study, we describe the utility of glycosidases to
characterize the glycosylation profiles of two recombinant
HIV-1 transmitted/founder Env oligomers based on the enve-
lope proteins (Envs) derived from a clade B transmitted/
founder virus, B.700010040.C9 (33), and from a clade C
transmitted/founder virus, C.1086 (1). HIV-1 Env is heavily
glycosylated, with at least 24 N-linked glycosylation sites (10,
17, 39, 45, 67, 69). Glycosylation profiles of HIV-1 Env have
been characterized by structural analysis of chemically or en-
zymatically released glycans (45, 46, 56) or by glycopeptide-
based analysis (10, 17, 19, 20, 29, 39, 65, 68, 69). In this study,
we employed a glycopeptide-based mass mapping approach
that includes a sequential digestion with glycosidases and tryp-
sin prior to liquid chromatography-electrospray ionization-
Fourier transform ion cyclotron resonance MS (LC/ESI-
FTICR MS) analysis to maximize glycosylation information
and determine the N-glycosylation profiles inherent to two
transmitted/founder Envs, where “transmitted/founder” Envs
are defined as Envs derived from the early env gene sequences
of acutely infected individuals that coalesce to a consensus env
gene sequence of the transmitted virus (1, 33). Our results
show that both transmitted/founder Envs had a similar degree
of glycosylation site occupancy, and 50% of the sites are
either variably utilized or completely nonutilized. When glyco-
sylation sites are utilized, 20% and 30% of glycosylation sites
on B.700010040.C9 gp140 C and C.1086 gp140 C, respec-
tively, are populated exclusively with high-mannose glycans.
Five conserved glycosylation sites in both transmitted/founder
Envs are populated with high-mannose glycans. Compared to
the glycosylation profiles of the Envs derived from viruses
isolated from chronic HIV-1 infections, B.JR-FL and
C.97ZA012 (19, 20), the transmitted/founder Envs differed in
their glycosylation patterns in terms of site occupancy and
regarding levels of complex glycans present compared to those
present on chronic HIV-1 recombinant Envs.
MATERIALS AND METHODS
Reagents. Ammonium bicarbonate, Trizma hydrochloride, Trizma base,
EDTA, high-performance liquid chromatography (HPLC)-grade acetonitrile
(CH3CN) and methanol (CH3OH), urea, dithiothreitol (DTT), Tris(2-carboxy-
ethyl)phosphine hydrochloride (TCEP), iodoacetamide (IAM), ammonium hy-
droxide, ammonium acetate, glacial acetic acid, and formic acid were purchased
from Sigma (St. Louis, MO). Water was purified using a Millipore Direct-Q3
water purification system (Billerica, MA). Sequencing-grade trypsin was ob-
tained from Promega (Madison, WI). Glycerol-free peptide-N-glycosidase F
(PNGase F) cloned from Flavobacterium meningosepticum and endo--N-acetyl-
glucosaminidase H (Endo H) cloned from Streptomyces plicatus, were purchased
from New England BioLabs (Ipswich, MA). Sialidase A cloned from Arthrobacter
ureafaciens and endo--N-acetylglucosaminidase F3 (Endo F3) cloned from
Elizabethkingia meningoseptica, were obtained from Prozyme (Hayward, CA) and
EMD Biosciences (Gibbstown, NJ), respectively.
Expression and purification of transmitted/founder HIV-1 subtype B and C
envelope proteins. B.700010040.C9 and C.1086 envelope proteins were con-
structed (41). Acute HIV-1 envelope gene sequences of B.700010040.C9 and
C.1086 were isolated from individuals with acute subtype B and subtype C HIV-1
infections, respectively, by single genome amplification (SGA) (1, 58). To pro-
duce recombinant soluble gp140 oligomer proteins, gp140 C env genes were
designed by introducing a stop codon before the membrane-spanning domain,
mutating two critical Arg residues in the gp120-gp41 cleavage site, and preserv-
ing all other regions of the extracellular domain of the env gene. The
B.700010040.C9 and C.1086 gp140 env genes were codon optimized by convert-
ing amino acid sequences to nucleotide sequences employing the codon usage of
highly expressed human housekeeping genes (4, 41), de novo synthesized (Blue
Heron, Bothell, WA), and cloned into pcDNA3.1 expression vector (Invitrogen,
Carlsbad, CA). The resulting recombinant plasmids were linearized by digestion
with restriction endonuclease SspI (Invitrogen, Carlsbad, CA) and used to gen-
erate stably transfected 293T cells (ATCC, Bethesda, MD) under selection of
hygromycin B (Sigma, St. Louis, MO) at 200 g/ml. Recombinant HIV-1
gp140C Envs were purified from serum-free supernatant of the stably trans-
fected 293T cells by lectin agarose beads (Galanthus nivalis; Vector Laboratories,
Burlingame, CA) (41) and stored at 80°C until use. Prior to any mass spectro-
metric experiments, Env samples were thawed and aliquoted into separate tubes
containing 75 g of the Env sample and stored at 80°C until analysis.
Glycosidase digestion of envelope proteins. Deglycosylation of Envs using
PNGase F was performed by incubating 75 g of the Env sample (protein
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concentration of 4 mg/ml) with 1 l of PNGase F solution (500,000 U/ml) for
a week at 37°C at pH 8.5. Endo H and Endo F3 deglycosylation experiments were
performed by incubating 75 g of the Env (protein concentration of 4 mg/ml)
with the enzyme solutions. For the Endo H deglycosylation experiment, samples
were denatured with 2 M urea in 100 mM Tris buffer (pH 5.5), followed by the
addition of 2 l of Endo H (5 U/ml). After thorough mixing, the reaction
mixture was incubated for 48 h at 37°C. In the Endo F3 deglycosylation exper-
iment, samples were deglycosylated by addition of 2 l of Endo F3 (5 U/ml) to
a reaction mixture containing 75-g Env samples in 50 M NH4C2H2O2 (pH
4.5). The reaction mixture was incubated for 2 weeks at 37°C. As a quality control
experiment, the Endo F3 and Endo H studies were first conducted on the HIV-1
Env B.JR-FL. The results from these experiments indicated that site occupancy
analysis with Endo H and Endo F3 produced results identical to those that
occurredwhen the site occupancy was determined by PNGase F. Desialylation
with sialidase A was performed by adding 2 l of sialidase A (5 U/ml) to 75-g
Env samples at pH 6.5, with the mixture incubated overnight at 37°C. Prior to
tryptic digestion, the pH of the deglycosylated Env samples was adjusted to 8.5
with 300 mM NH4OH. Deglycosylated Env samples were digested with trypsin as
described below.
Digestion of envelope proteins. The total protein concentration, which was
measured by absorbance, was 4 mg/ml, and samples containing 75 g of the
HIV-1 Envs were used for protein digestion. Proteins were denatured with 6 M
urea in 100 mM Tris buffer (pH 8.5) containing 3 mM EDTA and were fully
reduced using either 15 mM DTT or 5 mM TCEP at room temperature for 1 h.
TCEP was used for samples treated with glycosidases due to its stability and
efficiency at breaking disulfide bonds at low pH (25). Both TCEP- and DTT-
reduced samples were alkylated with 20 mM IAM at room temperature for
another hour in the dark. Excess IAM in both samples was quenched by adding
DTT to a final concentration of 25 mM, and the mixture was incubated for 20
min at room temperature. The reduced and alkylated Env samples were digested
with trypsin (30:1 protein/enzyme ratio) at 37°C and incubated overnight, fol-
lowed by a second trypsin addition under the same conditions. The resulting
HIV-1 envelope protein digest was either directly analyzed by LC/ESI-FTICR
MS or stored at 20°C until further analysis. To ensure reproducibility of the
method, protein digestion was performed at least three times on different days
with Env samples obtained from the same batch and analyzed with the same
experimental procedure.
Mass spectrometry. LC/ESI-FTICR MS experiments were performed using a
hybrid linear ion-trap (LIT) Fourier transform (FT) ion cyclotron resonance
mass spectrometer (LTQ-FT; ThermoScientific, San Jose, CA) directly coupled
to the Dionex UltiMate capillary LC system (Sunnyvale, CA) equipped with a
FAMOS well plate autosampler. Mobile phases utilized for the experiment
consisted of solvent A (99.9% deionized H2O plus 0.1% formic acid) and solvent
B (99.9% CH3CN plus 0.1% formic acid). Five microliters of the sample (7
M) was injected onto a C18 PepMap 300 column (300-m inside diameter [i.d.]
by 15 cm, 300 Å; LC Packings, Sunnyvale, CA) at a flow rate of 5 l/min. The
following CH3CN/H2O multistep gradient was used: 5% solvent B for 5 min
followed a linear increase to 40% solvent B in 50 min, and then a linear increase
to 90% solvent B in 10 min. The column was held at 95% solvent B for 10 min
for reequilibration. A short wash and blank run were performed between every
sample to ensure there was no sample carryover. The ESI source was operated
under the following conditions: source voltage of 2.8 kV, capillary temperature
of 200°C, and capillary offset voltage of 44 V. Data were collected in the positive-
ion mode in a data-dependent fashion in which the five most intense ions in an
FT scan at resolution (R)  25,000 at m/z 400 were sequentially and dynamically
selected for subsequent collision-induced dissociation (CID) in the LTQ linear
ion trap using a normalized collision energy of 30% and a 3-min dynamic
exclusion window followed by two neutral loss scans when a loss of a monosac-
charide unit was detected in the MS2 scan. (Note that under these conditions, the
resolution, R, at m/z 1,000 is 10,000, and at m/z 1,500, R is 6,700.)
Glycopeptide identification. Compositional analyses were performed using
GlycoPep DB (21), GlycoPep ID (28), and GlycoMod (9). Details of the analysis
for glycopeptides have been described previously (19, 20, 29). Briefly, for glyco-
peptides with a singly utilized glycosylation site, compositional analysis was
performed using the MS2 data. First, the peptide portion of a glycopeptide was
identified in the tandem-MS spectrum. The peptide sequence was elucidated
from the characteristic fragment of the glycosidic cleavage ion, Y1, using
GlycoPep ID. Once the peptide sequence was identified, plausible glycopeptide
compositions were obtained using the high-resolution MS data and GlycoPep
DB, and the putative glycan candidate was confirmed manually by identifying the
Y1 ion and inspecting the glycan fragmentation pattern from the tandem-MS
data. For glycopeptides with multiply utilized glycosylation sites, experimental
masses of glycopeptide ions from the high-resolution MS data were converted to
singly charged masses and submitted to GlycoMod. This program calculates
plausible glycopeptide compositions from the set of experimental mass values
entered by the user, compares these mass values with theoretical mass values,
and then generates a list of plausible glycopeptide compositions within a speci-
fied mass error. Plausible glycopeptide compositions in GlycoMod were deduced
by providing the mass of the singly charged glycopeptide ion, enzyme, protein
sequence, cysteine modification, mass tolerance, and possible types of glycans
present in the glycopeptide. Plausible glycopeptide compositions obtained from
the analysis were manually confirmed and validated from MS2 data.
Peptide identification. Deglycosylated peptides were identified by searching
raw data acquired on the hybrid LTQ FTICR mass spectrometer against a
custom HIV database with 107 protein entries, obtained from the Los Alamos
HIV sequence database (http://www.hiv.lanl.gov/content/), using Mascot, version
2.2.04 (Matrix Science, London, United Kingdom). The peak list was extracted
from raw files using BioWorksBrowser, version 3.5 (Thermo Electron Corpora-
tion). DTA files were searched specifying the following parameters: (i) enzyme,
trypsin; (ii) missed cleavage, 2; (iii) fixed modification, carbamidomethyl; (iv)
variable modification, methionine oxidation, carbamyl, HexNAc, and dHexNAc;
(v) peptide tolerance, 0.8 Da; and (vi) MS/MS tolerance of 0.4 Da. Peptides
identified from the Mascot search were manually validated from MS2 data to
ensure major fragmentation ions (b and y ions) were observed, especially for
peptides generated from PNGase F-treated Envs that contain N-to-D conver-
sions.
Hierarchical clustering of Envs based on glycosylation site occupancy. Clus-
tering analysis was performed for comparison of glycosylation site occupancy of
the two acute and chronic Envs. The protein sequences of the Envs were aligned
using ClustalW2 (37) to determine fixed, shifting, and missing glycosylation sites.
Note that missing glycosylation sites are due to mutation or deletion. A table for
glycosylation occupancy was generated, with each row corresponding to the site
occupancy of each glycosylation site arranged according to the Env sequence
position. The following values were used for site occupancy: 1 for a fully utilized
site; 0 for an unutilized or missing site; and between 0 and 1 for a variably utilized
site, specifically 0.25, 0.33, 0.5, and 0.67. These values were deduced depending
on the number of potential N-glycosylation (PNG) sites for a given tryptic
peptide and the degree of site occupancy. For tryptic peptides with (i) one PNG
site and site occupancy of 0 and 1, the value is 0.5, and for those with (ii) two
PNG sites and site occupancy of 0, 1, and 2, the values are 0.25, 0.33, 0.5, or 0.67,
depending on how they are occupied. Heirarchical clustering was performed
using the R language (version 2.11.1, 2010; R Foundation for Statistical Com-
putation) (27). The hclust function was used for clustering the column by the
Ward method for linkage. A heat map with a column dendrogram was generated
using the heatmap.2 function.
RESULTS
Characteristics of HIV-1 Env from transmitted/founder
viruses. The transmitted/founder Envs used in this study
were expressed in 293T stably transfected cell lines (7) and
were derived from a clade B transmitted/founder virus
(B.700010040.C9) (31) and a clade C transmitted/founder virus
(C.1086) (1) with the deletion of the cleavage site (C) in the
gp140 sequence. The full sequence alignment of the two trans-
mitted/founder Envs showing the five conserved regions, the
five hypervariable regions, and the gp41 region is shown in Fig.
1. Sequence alignment analysis using ClustalW2 (37) revealed
that the protein sequences of the transmitted/founder clade B
and C Envs were 71% identical. Potential N-linked glycosyl-
ation (PNG) sites are shown in red (Fig. 1), and overall, there
were 25 and 27 PNG sites for B.700010040.C9 gp140 and
C.1086 gp140, respectively. Comparison of the PNG sites of
the transmitted/founder Envs revealed that 17 of the PNG sites
were conserved. These sites are in the conserved Env regions
C1 (N88 and N130), C2 (N197, N241, N262, N276, and N289),
C3 (N334), and C4 (N448) and the hypervariable Env regions
V1 (N156), V3 (N301), and V4 (N386 and N392), as well as in
the gp41 region (N611, N616, N625, and N637). Numbering of
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glycosylation sites was based on the reference HIV-1 strain,
HXB2 (UniProtKB/Swiss-Prot accession no. P04578) (67).
Site-specific glycosylation analysis of Envs derived from
transmitted/founder viruses. We implemented an experimen-
tal workflow for the characterization of the glycosylation of the
transmitted/founder Envs, as shown schematically in Fig. 2A.
This workflow included an up-front complete and partial
enzymatic deglycosylation step using the endoglycosidases
PNGase F, Endo H, and Endo F3 and an exoglycosidase,
sialidase A, on separate aliquots of Env samples followed by an
in-solution trypsin digestion. The resulting Env digests were
analyzed by LC/ESI-FTICR MS, and glycopeptide composi-
tions were deduced using the software tools Mascot, GlycoPep
DB, GlycoMod, and GlycoPep ID (9, 21, 28), as shown in Fig.
2A. The inclusion of complete and partial deglycosylation in
the sample preparation step generated complementary MS
data sets from four separate glycosidase-treated Env samples
that were subsequently integrated to obtain the overall glyco-
sylation profiles of the transmitted/founder Envs. Our initial
efforts to characterize the glycosylation of these Envs without
the use of the glycosidases resulted in 	40% of the putative
glycosylation sites detected with 	30% of the glycan compo-
sitions detected. Therefore, the newly implemented ap-
proaches were designed to increase the glycosylation coverage
and maximize glycosylation information. Specifically, we ob-
tained complete coverage of the glycosylation sites and a more
than 2-fold increase in the number of glycan compositions
detected.
The glycosidases shown in Fig. 2B that were used in these
experiments have the following glycan specificities. (i) PNGase
F catalyzes the complete cleavage of glycans attached to the
glycosylated asparagine (N) residue in the consensus sequence
NXT/S/C, where X is any amino acid except proline, resulting
in the conversion of N to D. (ii) Endo H and Endo F3 catalyze
the cleavage of glycosidic bond between the two N-acetylglu-
cosamine (HexNAc) residues in the chitobiose core, generat-
ing N-glycosylation sites with HexNAc or fucosylated HexNAc
residues. Endo H cleaves only high-mannose and hybrid gly-
cans, while Endo F3 cleaves complex glycans with specificity
for bianternnary and trianternnary complex glycans (43, 61).
(iii) Sialidase A catalyzes the cleavage of sialic acid residues.
The use of these glycosidases followed by LC/ESI-FTICR anal-
ysis provided complementary information on the degree and
type of glycosylation on B.700010040.C9 gp140 and C.1086
gp140 due to their selective glycan specificities. For instance,
Env samples treated with Endo H permitted analysis of glyco-
peptides with complex glycans, while Env samples treated with
Endo F3 permitted analysis of glycopeptides with high-man-
nose and hybrid glycans. In addition to the glycopeptide spe-
cies, Endo H- and Endo F3-treated samples generated pep-
tides with HexNAc or fucosylated HexNAc residues, thereby
providing information on site occupancy.
FIG. 1. Sequence alignment of the early transmitted Env immunogens B.700010040.C9 gp140 C and C.1086 gp140 CF. Dashes indicate gaps
in amino acid sequence and the location of the variable (V1 to V5) and conserved (C1 to C5) regions, with potential glycosylation sites in red. To
standardize the sequence positions, the numbering was based on that of the reference HIV strain HXB2.
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Degree of glycosylation site occupancy. Using the experi-
mental workflow described in the previous section, we have
identified all of the 25 and 27 potential N-linked glycosylation
(PNG) sites from the tryptic digest of B.700010040.C9 gp140
and C.1086 gp140 Envs, respectively. Table 1 shows the iden-
tified glycopeptides with their corresponding glycosylation site
occupancy. The mapping of the 25 and 27 PNG sites from
B.700010040.C9 gp140 and C.1086 gp140, respectively, was
accomplished by 20 tryptic peptides with single and multiple
PNG sites per Env that were detected from the LC/ESI-
FTICR MS and MS/MS analyses of endoglycosidase-treated
Env samples. Deglycosylated peptides generated from en-
doglycosidase-treated Env samples would either have corre-
sponding N-to-D conversion when PNGase F is used, or
HexNAc/fucosylated HexNAcs are attached to glycosylated as-
paragine in the consensus sequence after treatment with Endo
H or Endo F3. We relied mostly on the data obtained from
Endo H- and Endo F3-treated Env samples to discern glyco-
sylation site occupancy due the fact that a larger mass shift of
203.0793 Da (when a single HexNAc remains attached to N) or
349.1373 Da (when a fucosylated HexNAc remains attached to
N) is observed for deglycosylated peptides, thus permitting the
most conclusive assignments. With PNGase F, assignment of
glycosylation site occupancy is not always straightforward due
to a relatively small mass shift (0.9840 Da) when both degly-
cosylated and nonglycosylated forms of the same peptide co-
elute and the fact that potential deamidation artifacts could
occur during digestion, resulting in false-positive identification.
Accordingly, data obtained from PNGase F-treated Env sam-
ples were used only to determine glycosylation site occupancy
of glycopeptides that were not detected from Endo H- and
Endo F3-treated samples.
A representative piece of LC/ESI-FTICR MS data from the
Endo H-treated clade C Env sample C.1086 gp140 depicts two
peptides bearing HexNAc residues coeluting with several
glycopeptides with the peptide portion EVHNVWATHACVP
TDPNPQEMVLAN88VTENFNMWK (Fig. 3). The PNG is
shown in boldface. Each identified peak in this high-resolution
mass spectrum was validated from MS/MS data as described in
Materials and Methods. This spectrum shows three partially
deglycosylated peptides, EVHNVWATHACVPTDPNPQEM
VLAN88VTENFNMWK, with one utilized glycosylation site
FIG. 2. (A) Experimental workflow for the glycopeptide-based mass mapping approach that includes a sequential digestion with endoglyco-
sidase and trypsin. Glycopeptide compositions and site occupancy are determined using software-based analysis tools. (B) Glycan specificities of
the glycosidases used to cleave glycans from substrate.
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and, N241VSTVQCTHGIKPVVSTQLLLN262GSLAEEEIIIR,
with one and two utilized glycosylation sites. In addition to
these deglycosylated peptides, the nonglycosylated form of the
peptide, N241VSTVQCTHGIKPVVSTQLLLN262GSLAEEEI
IIR, was also detected. These results are shown in Table 1,
which summarizes the degree of glycosylation site occupancy
for the two transmitted/founder Envs. The site occupancy anal-
ysis revealed that out of the 25 and 27 sites in B.700010040.
C9 gp140 and C.1086 gp140, respectively, 13 sites in
B.700010040.C9 gp140 and 20 sites in C.1086 gp140 are vari-
ably utilized. In addition to these variably utilized sites, the
glycosylation sites N398 and N637 in B.700010040.C9 gp140
and the glycosylation sites N401 and N465 in C.1086 gp140 are
not glycosylated at all. Not all of the variably utilized and
unutilized glycosylation sites are located the same region of the
two Envs when mapped onto the Env structure. Only 11 of
the variably utilized glycosylation sites are common to both of
the transmitted/founder Envs, and these sites are located in the
V1-V2 (N156), C2 (N197, N276, and N289), V3 (N301), C3
(N334), V4 (N408/N409), C4 (N448), V5 (N462/N463), and
gp41 (N611 and N616) regions. It should be noted that the env
genes that expressed the transmitted Envs were codon opti-
mized, as mentioned in Materials and Methods. At this point,
it is unknown whether or not codon optimization has an impact
on glycosylation site occupancy. Both the proteins in Fig. 1 and
the proteins we characterized previously were codon optimized
in the same fashion, so we would expect that in the unlikely
event that codon optimization impacts glycosylation site occu-
pancy, it would impact all of the proteins in Fig. 1 in the same
manner—for example, all of the proteins would potentially
have fewer unoccupied sites, if codon optimization were not
done. Thus, codon optimization of recombinant env genes
would not be expected to explain glycan differences observed
between the transmitted/founder Envs and the chronic Envs.
TABLE 1. Glycopeptides detected from LC/ESI-FTICR MS analysis
Glycopeptide sequencea No. of potentialglycosylation sites Sites occupied
B.700010040.C9 gp140 C
N88VTENFNMWENNMVEQMHEDIISLWDQSLKPCVK 1 1
LTPLCVTLN130CTDLGN136VTN139TTNSNGEMMEK 3 2 and 3
N156CSFK 1 0 and 1
LDVVPIN186DTR 1 1
LVSN197TSVITQAPCK 1 0 and 1
QFIGTGPCTN241VSTVQCTHGIRPVVSTQLLLN262GSLAEEEVVIR 2 2
SVN276FSDNAK 1 0 and 1
TIIVQLN289K 1 0 and 1
SVEITCTRPNN301NTR 1 0 and 1
AYCEIN334GTEWHSTLK/KAYCEIN334GTEWHSTLK 1 0 and 1
EQYN356K/LREQYN356K 1 1
TIVFN362R 1 0 and 1
SSGGDPEIVMYSFNCGGEFFYCN386STK 1 1
LFN392STWPWN398DTK 2 1
GSHDTN409GTLILPCK 1 0 and 1
CSSN448ITGLLLLR 1 0 and 1
DGGYESN463ETDEIFRPGGGDMR 1 0 and 1
LICTTTVPWN611TSWSN616K 2 0, 1, and 2
SLEQIWN625MTWMEWER 1 1
EIDN637YTGYIYQLEIEESQNQQEK 1 0
C.1086 gp140 C
EVHNVWATHACVPTDPNPQEMVLAN88VTENFNMWK 1 0 and 1
LTPLCVTLN130CTNVK 1 0 and 1
GN137ESDTSEVMK 1 0 and 1
N156CSFK 1 0 and 1
LDVVPLNGN184SSSSGEYR 1 1
LINCN197TSAITQAPCK 1 0 and 1
CNN230K 1 1
TFN234GTGPCR 1 0 and 1
N241VSTVQCTHGIKPVVSTQLLLN262GSLAEEEIIIR 2 0, 1, and 2
SEN276LTNNAK 1 0 and 1
TIIVHLN289ESVNIVCTRPNN301NTR 2 0, 1, and 2
QAHCNIN334ESK 1 0 and 1
WN339NTLQK 1 0 and 1
GEFFYCN386TSDLFN392GTYR 2 0, 1, and 2
N397GTYN401HTGR 2 1
SSN408GTITLQCK/SSN408GTITLQCKIK 1 0 and 1
AIYAPPIEGEITCNSN448ITGLLLLR 1 0 and 1
DGGQSN462ETN465DTETFRPGGGMR 2 0 and 1
LICTTAVPWN611SSWSN616K 2 0, 1, and 2
SQNEIWGN625MTWMQWDR 1 1
EINN637YTNTIYR 1 1
a PNGs are shown in boldface.
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Partial deglycosylation using Endo H and Endo F3. The use
of Endo H and Endo F3 for partial release of N-glycans affords
several benefits. First as described in the previous section and
elsewhere (22–24, 44, 59, 60), these enzymes can be used to
unambiguously identify glycosylation site occupancy since a
clear distinction is made between partially deglycosylated and
nonglycosylated forms of the same peptide. In addition to the
above benefit, we show that these enzymes are useful for the
reduction of glycan heterogeneity in the LC/MS data, which
facilitates the characterization of glycopeptides that do not
ionize efficiently or are not detected at all when all of the
glycopeptides are present. An illustrative example is shown in
Fig. 4. This figure shows high-resolution mass spectra of two
clade B Env samples, one digested with trypsin (Fig. 4A) and
the other sequentially digested with Endo H and trypsin (Fig.
4B). The data show a glycopeptide-rich fraction with two co-
eluting glycopeptides containing the peptide portions AYCEI
N334GTEWHSTLK and DGGYESN463ETDEIFRPGGG
DMR. Glycan compositions of the observed glycopeptide
peaks in the mass spectra were verified from tandem-MS data
(data not shown) and software analysis tools. Compositional
analysis of the glycopeptide peaks observed in Fig. 4A reveals
that glycopeptides containing the peptide portion AYCEIN334
GTEWHSTLK were mostly high-mannose and hybrid-type
glycopeptides coeluting with several complex type glycopep-
tides containing the peptide portion DGGYESN463ETDEIFR
PGGGDMR. Comparison of the MS data obtained from the
Endo H-treated B.700010040.C9 gp140 sample in the same
elution window shows ions with higher abundance correspond-
ing glycopeptides containing complex glycans and the peptide
portion DGGYESN463ETDEIFRPGGGDMR and smaller
ions corresponding to complex glycopeptides with peptide por-
tion AYCEIN334GTEWHSTLK, with and without sialylation
(Fig. 4B). Endo H cleaves high-mannose/hybrid glycans, while
complex glycans are unaffected, thereby reducing glycan het-
erogeneity. As a result, improvements in both glycosylation
coverage and signal/noise (S/N) ratio were observed for glyco-
peptides with peptide portion DGGYESN463ETDEIFRPGG
GDMR, and the detection of both sialylated and nonsialylated
species with peptide portion AYCEIN334GTEWHSTLK was
also possible (Fig. 4B). Clearly, the sequential digestion with
Endo H and trypsin helps minimize ionization suppression,
enhances ionization of glycopeptides outside the glycan spec-
ificity of Endo H, and increases the dynamic range of the
experiment and therefore increases glycopeptide coverage.
We also report another benefit from using the endoglycosi-
dases. Due to the distinct glycan specificities of Endo H and
Endo F3, the type of glycan attached at a particular glycosyl-
ation site of multiply glycosylated peptides can be deduced.
More specifically, the use of these enzymes facilitates the de-
termination of whether the site is populated with either high-
mannose/hybrid-type glycans, complex-type glycans, or both.
FIG. 3. LC/ESI-FTICR mass spectrum of the Env C.1086 gp140 C, which was sequentially digested with Endo H and trypsin. Endo H cleaves
high-mannose and hybrid glycans, leaving a single HexNAc on the glycosylated site while complex glycans are unaffected. Several peaks are present
resulting from Endo H digestion on two tryptic peptides, EVHNVWATHACVPTDPNPQEMVLAN88VTENFNMWK in the C1 region and
N241VSTVQCTHGIKPVVSTQLLLN262GSLAEEEIIIR in the C2 region. These peptides contain one and two HexNAcs, and these species
coelute with glycopeptides with complex-type glycans and peptide portion EVHNVWATHACVPTDPNPQEMVLAN88VTENFNMWK. In ad-
dition, the nonglycosylated form of N241VSTVQCTHGIKPVVSTQLLLN262GSLAEEEIIIR was also observed. The peptide sequences were
confirmed from tandem-MS data. This is a demonstration of using endoglycosidases to identify site occupancy for glycopeptides.
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One example showing this benefit of using the glycosidases is in
the analysis of glycopeptides from C.1086 gp140 with peptide
portion TIIVHLN289ESVNIVCTRPNN301NTR, bearing two
potential glycosylation sites at N289 and N301. Figure 5A
shows the high-resolution mass spectrum of the glycopeptides
that were not treated with Endo H or Endo F3. The data show
the quadruply charged glycopeptide peaks with both of the
glycosylation sites utilized. Compositional analysis of each gly-
copeptide peak in the spectrum is not straightforward due to
ambiguity in the tandem-MS data arising from less intense
peaks, missing diagnostic peaks, and peaks that exist in several
charge states. Plausible compositions obtained from the com-
positional analysis of the quadruply charged peaks in Fig. 5A
indicated that one of the sites is populated with high-mannose
glycans and the other is populated with either bi- or trianten-
nary complex glycans with core fucosylation (see Table S2 in
the supplemental material). However, in the analysis of Env
samples treated with Endo H or Endo F3, characterization of
the glycan profile from these glycopeptides was straightforward
(Fig. 5B and C). MS data of samples treated with Endo H (Fig.
5B) show glycopeptides containing one site occupied with com-
plex glycans and the other with a single HexNAc. In contrast,
when the same Env is treated with Endo F3 instead of Endo H
(Fig. 5C), the glycopeptides for this part of the protein se-
quence have one occupied site containing high-mannose gly-
cans and the other site containing fucosylated HexNAc. Taken
together, the data in Fig. 5B and C clearly show that one of the
two sites on this peptide contains high-mannose glycans, while
the other site contains complex glycans. These assignments are
supported by the MS/MS data shown in Fig. 5D and E. How-
FIG. 4. LC/ESI-FTICR mass spectra of a glycopeptide-rich fraction showing two coeluting glycopeptides found in the C3 region and V5 loop
for the B.700010040.C9 gp140 C Env sample after trypsin digestion (A) and sequential digestion (B) with Endo H and trypsin eluting between
25.6 and 26.7 min. The number of scans for each spectrum was 11. Asterisks in the MS data denote glycopeptide peaks. Green and yellow stars
on top of asterisks in panel A denote glycopeptides with high-mannose and hybrid glycans, respectively. Glycan compositions of each observed
glycopeptide peak in the mass spectra were verified from tandem-MS data. These data show that after Endo H treatment, strongly ionizing
high-mannose and hybrid glycopeptides are depleted and low-abundance glycopeptides that were suppressed in panel A now are detectable in
panel B.
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ever, identification of which site is populated with high-man-
nose or complex glycans is not possible without the data in Fig.
5F. To accurately determine which site is populated with high-
mannose or complex glycans, Env samples were treated with a
combination of Endo H and Endo F3 to cleave all glycans
except for the core HexNAc’s with and without the attached
core fucose. Tandem-MS analysis of the triply charged peak at
m/z 1,039.5404 (Fig. 5F), corresponding to TIIVHLN289ESV
FIG. 5. LC/ESI-FTICR MS data of the doubly glycosylated peptide TIIVHLN289ESVNIVCTRPNN301NTR in the C.1086 gp140 C sample
after trypsin digestion (A), sequential digestion with Endo H and trypsin (B), and sequential digestion with Endo F3 and trypsin (C). Glycan
compositions in these high-resolution spectra (B and C) are verified from MS/MS data in shown in panels D and E. Note that panel D corresponds
to the representative MS/MS data of a glycopeptide peak in panel B, while panel E corresponds to the representative MS/MS data of a glycopeptide
peak in panel C. (F) MS/MS data of the peptide generated from sequential digestion of C.1086 gp140 C Env sample with Endo F3, Endo H, and
trypsin, confirming that N289 is populated with high-mannose glycans, while N301 is populated with complex glycans.
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NIVCTRPNN301NTR, with one site containing a single
HexNAc and the other containing fucosylated HexNAc, re-
vealed that N289 is populated with high-mannose glycans,
while N301 is populated with complex glycans. These results
show that Endo H and Endo F3 provide complementary in-
formation about the glycan profile of glycopeptides, and in
some cases, they can be used to determine which glycans are
present at which sites on multiply glycosylated peptides.
Glycan profile of transmitted/founder Envs. Using the
method described in Fig. 2A, glycan compositions were de-
duced from high-resolution and tandem mass spectra. The
tandem-MS data were evaluated to elucidate the glycopep-
tide composition on the basis of the following criteria: (i)
the presence of a fragment ion corresponding to the glyco-
sidic cleavage ion, Y1, to determine the peptide portion of
the glycopeptide, (ii) the presence of oxonium ions in the
low-mass region (m/z 	1,000), and (iii) the series of peaks
that are separated by the mass of the monosaccharide units.
Figure 6A shows a representative LC/ESI-FTICR mass
spectrum from an elution window of glycopeptides located
in the V2-C2, C2, and V4 regions for B.700010040.C9 gp140.
The glycan composition of each peak in this high-resolution
mass spectrum was determined using tandem-MS data as
just described. Two examples of the MS/MS data are shown
in Fig. 6B and C. The identified unique glycan compositions
deduced from this analysis were verified with several exper-
imental runs to check the reproducibility of the measure-
ments in terms of glycan compositions and coverage. Over-
all, a high degree of glycosylation coverage was obtained, as
demonstrated by the identification of 400 unique glyco-
peptide compositions per Env. Table 2 shows a partial list of
the glycopeptides bearing high-mannose, hybrid, and com-
plex glycans identified in this study (see Tables S1 and S2 in
the supplemental material for the complete list). Akin to the
glycan profile of the four Envs that we previously reported
(19, 20), the glycosylation sites of the two transmitted/
founder Envs, when utilized, are also populated with high-
mannose, hybrid, and complex glycans with multiantennary
structures with and without sialylation and core fucosyla-
tion. In addition, we also identified peptides with PNG sites
modified with a single HexNAc with and without core fuco-
sylation from Env samples that were not treated with glyco-
FIG. 6. (A) LC/ESI-FTICR mass spectrum of the glycopeptide-rich fraction showing three coeluting glycopeptides in the V2-C2, C2, and V4
regions for B.700010040.C9 gp140. (B and C) LC/ESI-MS/MS spectra showing the fragmentation pattern of the glycopeptides in the V4 loop
(B) and the V2-C2 region (C). Note that peaks with asterisks in panel A correspond to glycopeptides.
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sidases. Finally, in comparison to the Envs that we have
previously analyzed, the transmitted/founder Envs have a
higher level of sialylation.
While a very high degree of glycosylation diversity was
detected among the characterized glycosylation sites, not all
of the glycopeptides could be fully accounted for, even with
the extreme measures that were undertaken to obtain full
glycosylation coverage. Of the 20 and 21 tryptic peptides
with single and multiple glycosylation sites that were iden-
tified for both transmitted/founder Envs, the glycan profile
of the glycopeptide bearing three PNG sites in the V1-V2
loop with peptide portion LTPLCVTLN130CTDLGN136VT
N139TTNSNGEMMEK from B.700010040.C9 gp140 was not
identified. This particular glycopeptide has a high-mass pep-
tide backbone (m/z 3,327) with two and three of the three
PNG sites utilized, as determined from PNGase F-treated
Env samples (Table 1). Due to the inherent low ionization
efficiency of high-mass glycopeptide species, peaks corre-
sponding to this glycopeptide have relatively low intensity
and have high charge states that are not completely resolved
in the mass spectrum. In addition to this peptide, we are
unable to characterize the glycan profiles of two glycopep-
tides from B.700010040.C9 gp140. The first of these two
peptides contains PNG sites at N611 and N616, while the
second contains the site at N625. These peptides were de-
tected with a single HexNAc and/or fucosylated HexNAc
only from Env samples treated with Endo H and Endo F3.
Results obtained from glycosidase-treated Env samples re-
TABLE 2. Representative glycopeptide compositions for B.700010040.C9 gp140 C and C.1086 gp140 Ca
Env domain Chargestate
m/z Mass
error (ppm) Peptide sequence
b Glycan composition
Experimental Theoretical
B.700010040.C9
gp140 C
C1 4
 1,552.6714 1,552.6675 3 NVTENFNMWENNMVEQMHE
DIISLWDQSLKPCVK
Hex5HexNAc6
4
 1,564.4305 1,564.4149 10 NVTENFNMWENNMVEQMHE
DIISLWDQSLKPCVK
Hex6HexNAc4NeuNAc1
4
 1,542.4202 1,542.4109 6 NVTENFNMWENNMVEQMHE
DIISLWDQSLKPCVK
Hex6HexNAc5
4
 1,615.1600 1,615.1847 15 NVTENFNMWENNMVEQMHE
DIISLWDQSLKPCVK
Hex6HexNAc5NeuNAc1
4
 1,593.2045 1,593.1807 15 NVTENFNMWENNMVEQMHE
DIISLWDQSLKPCVK
Hex6HexNAc6
V2 2
 1,455.6338 1,455.6340 0.1 LDVVPINDTR Hex5HexNAc4Fuc1
2
 1,601.1771 1,601.1817 3 LDVVPINDTR Hex5HexNAc4Fuc1NeuNAc1
2
 1,746.7469 1,746.7294 10 LDVVPINDTR Hex5HexNAc4Fuc1NeuNAc2
2
 1,557.1775 1,557.1737 2 LDVVPINDTR Hex5HexNAc5Fuc1
2
 1,260.5483 1,260.5521 3 LDVVPINDTR Hex6HexNAc2
V4 2
 1,444.0971 1,444.0999 2 LFNSTWPWNDTK Hex6HexNAc2
2
 1,525.1272 1,525.1263 1 LFNSTWPWNDTK Hex7HexNAc2
2
 1,606.1508 1,606.1527 1 LFNSTWPWNDTK Hex8HexNAc2
C4-V5 3
 1,227.4659 1,227.4860 16 DGGYESNETDEIFRPGGGDMR Hex6HexNAc2
3
 1,770.3555 1,770.3467 5 DGGYESNETDEIFRPGGGDMR Hex6HexNAc5Fuc1NeuNAc3
3
 1,862.7033 1,862.7187 8 DGGYESNETDEIFRPGGGDMR Hex7HexNAc7Fuc1NeuNAc2
C.1086 gp140 C
C2 2
 957.3689 957.3561 3 CNNK Hex6HexNAc2
2
 1,038.3882 1,038.3825 5 CNNK Hex7HexNAc2
2
 1,119.4048 1,119.4089 4 CNNK Hex8HexNAc2
2
 1,200.4365 1,200.4353 1 CNNK Hex9HexNAc2
5
 1,373.2330 1,373.2182 11 NVSTVQCTHGIKPVVSTQLLLN
GSLAEEEIIIR
Hex15HexNAc4
5
 1,405.6548 1,405.6288 18 NVSTVQCTHGIKPVVSTQLLLN
GSLAEEEIIIR
Hex16HexNAc4
5
 1,438.0554 1,438.0394 11 NVSTVQCTHGIKPVVSTQLLLN
GSLAEEEIIIR
Hex17HexNAc4
5
 1,470.3994 1,470.4499 34 NVSTVQCTHGIKPVVSTQLLLN
GSLAEEEIIIR
Hex18HexNAc4
C2-V3 4
 1,509.6629 1,509.6447 12 TIIVHLNESVNIVCTRPNNNTR Hex13HexNAc6Fuc1
4
 1,499.4001 1,499.3880 8 TIIVHLNESVNIVCTRPNNNTR Hex14HexNAc5Fuc1
4
 1,622.9858 1,622.9611 15 TIIVHLNESVNIVCTRPNNNTR Hex14HexNAc6Fuc1NeuNAc1
V4 3
 1,167.7907 1,167.7895 1 NGTYNHTGR Hex6HexNAc6NeuNAc1
3
 1,270.5169 1,270.4931 19 NGTYNHTGR Hex7HexNAc6Fuc1NeuNAc1
3
 1,367.5176 1,367.5249 5 NGTYNHTGR Hex7HexNAc6Fuc1NeuNAc2
3
 1,464.5866 1,464.5567 20 NGTYNHTGR Hex7HexNAc6Fuc1NeuNAc3
a The complete list is found in Tables S1 and S2 in the supplemental material.
b PNGs are shown in boldface.
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vealed that the PNG sites at N611 and N616 are variably
utilized, while the PNG site at N625 is fully utilized.
For the glycosylation sites that were fully characterized, the
glycan distribution of the transmitted/founder Envs was de-
duced. Glycan compositions of each glycopeptide were sorted
and broadly grouped according to the criteria used in our
previous studies (19, 20). The glycan profile of each glycopep-
tide with either single or multiple glycosylation sites is repre-
sented by a pair of bars denoting the relative percentage of the
type of glycan (high mannose or processed) arranged accord-
ing to the Env sequence position, as shown in Fig. 7. The bar
graph illustrates the differential glycan profiles between the
two transmitted/founder Envs characterized herein, along with
those of previously characterized Envs derived from chronic
infections (19, 20). Comparison of the glycan profiles of the
transmitted/founder Envs C.1086 gp140 and B.700010040.C9
gp140 reveals that C.1086 gp140 has more sites with exclusively
high-mannose glycans (8 out of 27 PNG sites, or 30%) than
B.700010040.C9 gp140 (5 out of 25 PNG sites, or 20%). Be-
tween the two transmitted/founder Envs, there are five con-
served glycosylation sites bearing exclusively high-mannose
glycans. These glycosylation sites are located in the outer do-
main, C2 (N241 and N262) and C4 (N448) regions, and the V4
loop (N386 and N392). The conserved high-mannose glycan
profile in these regions of the Env indicates that both Envs
have similar protein conformations proximal to these glycosyl-
ation sites.
DISCUSSION
Transmitted/founder viruses are those quasispecies of virus
that establish productive infection in the first stages of acute
HIV-1 infection (33). The founder viral quasispecies that es-
tablishes productive infection is initially homogeneous in 70 to
80% of subjects but diversifies, due to both random errors in
reverse transcriptase and immune selective pressures (1, 32, 33,
38). The viral Env in acute HIV-1 infection has shorter variable
loops and fewer potential glycosylation sites than chronic Envs
(13, 36, 40, 42, 55). Information regarding the global glycosyl-
ation patterns of transmitted/founder Envs has been unavail-
able. As a first step toward characterizing transmitted/founder
Env glycans, we have determined the degree of glycosylation
site occupancy and characterized the founder/transmitted Env
glycosylation patterns by elucidating the glycan motif at each
potential glycosylation site on 293T cell-derived recombinant
envelope proteins. While these analyses are not of Env derived
from virus from CD4
 T cells, these studies report the tech-
nologies needed for this next study of CD4
 T-cell-derived
virus and as well demonstrate that recombinant founder Envs
have distinct glycosylation patterns compared to chronic Envs.
The data reported in this study, as summarized in Fig. 7 and
fully reported in Tables S1 and S2 in the supplemental mate-
rial, show that founder Env glycosylation sites are populated
with high-mannose, hybrid, and complex glycans containing
multianternnary structures with and without sialylation and
core fucosylation; additionally, single HexNAcs with and with-
out core fucosylation were also detected, even without the use
of endoglycosidases. One distinctive glycan pattern of the two
transmitted/founder Envs is that at least 20% of the sites were
populated exclusively with high-mannose glycans, and five
of these high-mannose-containing glycosylation sites (N241,
N262, N386, N392, and N448) are conserved.
Having determined the glycan profiles of transmitted/
founder Envs, an important question was whether the overall
FIG. 7. Glycan profiles on each identified glycosylation site of Env immunogens derived from viruses isolated from acute (C.1086 gp140 C and
B.700010040.C9 gp140 C) and chronic (B.JR-FL gp140 CF and C.97ZA012 gp140 CFI) HIV-1 infections. Glycan compositions (in percent-
ages) were broadly categorized into two classes—high mannose and processed glycans—and arranged according to sequence position. Processed
glycans include hybrid and complex glycans. Data presented for B.JR-FL and C.97ZA012 were obtained from our previous studies (19, 20).
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glycan profiles of founder Envs varied compared to those of
chronic Envs. To identify the trends and highlight the differ-
ences in the glycosylation patterns, we compared the glycan
profiles of chronic Envs, B.JR-FL gp140 and C.97ZA012
gp140, with those of the transmitted/founder Envs, C.1086
gp140 and B.700010040.C9 gp140. Data shown in Fig. 7 dem-
onstrate several glycan features that differ with chronic versus
founder Envs analyzed. (i) The transmitted/founder Envs had
more high-mannose content compared to chronic Envs. The
high level of high-mannose glycans observed suggested that
transmitted/founder Envs may be adopting different structural
features than chronic Envs since high-mannose glycans are
known to promote protein folding and stabilize protein con-
formation (63, 64). (ii) Within clade C Envs, C.1086 gp140 and
C.97ZA012 gp140, the glycosylation sites located in the C2
region (N230, N241, and N262) and the V3 loop, N334 for
C.1086 and N332 for C.97ZA012, bear a similar glycosylation
pattern consisting of predominantly high-mannose glycans.
This finding is in agreement with our previous study (19),
indicating that clade C Envs display a clade-specific pattern in
these regions. (iii) The glycan profiles of the four Envs in the
C1 region and the V1/V2 loops are also similar among all four
proteins, wherein glycosylation sites bear predominantly pro-
cessed glycans either with or without sialylation. This result
suggested that these regions were accessible to glycotrans-
ferases and therefore were solvent exposed. Finally (iv) on the
basis of the transmitted/founder and chronic Envs that we
analyzed, the two transmitted/founder Envs have relatively
similar glycan profiles regardless of clade, while chronic Envs
showed more clade-specific glycan profiles.
Another key characteristic glycosylation feature inherent in
HIV-1 Envs is the variation in the degree of glycosylation site
occupancy. The degree to which a particular site will be mod-
ified with glycans in the ER largely depends on the protein
sequence, availability of the glycosylation site, enzyme kinetics,
and substrate concentration (30). We demonstrated that trans-
mitted/founder Envs have 13 and 20 PNG sites that are vari-
ably utilized in B.700010040.C9 gp140 and C.1086 gp140, re-
spectively, and both have two PNG sites that are not utilized at
all. The chronic Env, B.JR-FL gp140, has seven sites that are
not utilized at any time and one site that is variably utilized,
while C.97ZA012 gp140 has two sites that are variably utilized
(19, 20). Direct comparison of the glycosylation site occupan-
cies among the Envs revealed that both transmitted/founder
Envs have more sites that are variably utilized than B.JR-FL
gp140 and C.97ZA012 gp140. To determine whether these
glycosylation data can be used to group the Envs based on
glycosylation site occupancy, we used one-dimensional hierar-
chical clustering to classify the glycosylation site occupancy
profiles of the four Envs. A heat map was generated with a
corresponding dendrogram to illustrate the clustering patterns
of the four Envs (Fig. 8). The value used for site occupancy is
between 0 and 1, depending on whether the glycosylation site
is unutilized or missing, utilized, and variably utilized (see
Materials and Methods). Interestingly, the data separate into
three distinct clusters: two distinct clusters representing
the characteristic glycosylation site occupancy profiles of the
chronic Envs B.JR-FL gp140 and C.97ZA012 gp140 and one
cluster for both C.1086 gp140 and B.700010040.C9 gp140.
The results indicate that glycosylation site occupancy profiles
FIG. 8. Heat map generated from the hierarchical clustering anal-
ysis of the glycosylation site occupancy of the early and late Env
immunogens. Each column represents the glycosylation site occupancy
of each Env immunogen. The dendrogram for glycosylation occupancy
clustering is shown on the top.
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for transmitted/founder Envs were similar to each other, while
glycosylation site occupancy profiles for chronic Envs showed a
higher degree of diversity, as they clustered separately from the
transmitted/founder Envs, and as well clustered separately
from each other. One important aspect of this work going
forward is to resolve the issue of how closely the recombinant
transmitted/founder Envs’ glycosylation profiles mimic those
on the virus, since it has been recently reported that glycan
processing may be different with membrane-associated gp160
compared to soluble gp140 (15, 45).
In conclusion, we demonstrate the glycosylation profiles of
transmitted/founder Envs using mass spectrometry in a glyco-
sylation site-specific fashion. Our experimental workflow that
included up-front complete and partial deglycosylation steps
prior to trypsin digestion proved to be necessary to obtain a
high degree of glycosylation coverage and to facilitate the
characterization of the glycosylation patterns of two recombi-
nant transmitted/founder Envs. Sequential digestion with gly-
cosidases and trypsin prior to mass analysis allowed for the
unambiguous identification of glycosylation site occupancy,
identification of the type of glycan attached on a particular
glycosylation site, and reduction in glycan heterogeneity. This
approach has facilitated the characterization of glycopeptides
that do not ionize efficiently or are not detected at all when all
glycopeptides are present. Our results show that both
B.700010040.C9 gp140 and C.1086 gp140 have similar degrees
of glycosylation site occupancy and similar glycan profiles. This
glycosylation profile is markedly different from those of
chronic Envs B.JR-FL gp140 and C.97ZA012 gp140 in their
degree of site occupancy and in the levels of complex glycans.
Since glycosylation is known to affect Env immunogenicity,
determination of glycan characteristics of different Envs should
provide important correlates of antigenicity and immunogenic-
ity of Env vaccine candidates.
ACKNOWLEDGMENTS
This work was supported by NIH grant RO1RR026061 to H.D.,
grant PO1AI61734, the Center for HIV/AIDS Vaccine Immunology
grant from the Division of AIDS, NIAID, NIH, and Collaboration for
AIDS Vaccine Discovery grant from the Bill and Melinda Gates Foun-
dation to B.F.H.
We also acknowledge the Analytical Proteomics Laboratory at KU
for instrument time, technical assistance with the production of acute
HIV-1 Env from Ashleigh Nagel, and helpful discussions with Ronald
Swanstrom, Beatrice Hahn, and George Shaw.
REFERENCES
1. Abrahams, M. R., et al. 2009. Quantitating the multiplicity of infection with
human immunodeficiency virus type 1 subtype C reveals a non-Poisson
distribution of transmitted variants. J. Virol. 83:3556–3567.
2. An, H. J., J. W. Froehlich, and C. B. Lebrilla. 2009. Determination of
glycosylation sites and site-specific heterogeneity in glycoproteins. Curr.
Opin. Chem. Biol. 13:421–426.
3. An, H. J., S. R. Kronewitter, M. L. de Leoz, and C. B. Lebrilla. 2009.
Glycomics and disease markers. Curr. Opin. Chem. Biol. 13:601–607.
4. Andre, S., et al. 1998. Increased immune response elicited by DNA vacci-
nation with a synthetic gp120 sequence with optimized codon usage. J. Virol.
72:1497–1503.
5. Binley, J. M., et al. 2010. Role of complex carbohydrates in human immu-
nodeficiency virus type 1 infection and resistance to antibody neutralization.
J. Virol. 84:5637–5655.
6. Budnik, B. A., R. S. Lee, and J. A. J. Steen. 2006. Global methods for protein
glycosylation analysis by mass spectrometry. Biochim. Biophys. Acta 1764:
1870–1880.
7. Chakrabarti, B. K., et al. 2002. Modifications of the human immunodefi-
ciency virus envelope glycoprotein enhance immunogenicity for genetic im-
munization. J. Virol. 76:5357–5368.
8. Chohan, B., et al. 2005. Selection for human immunodeficiency virus type 1
envelope glycosylation variants with shorter V1-V2 loop sequences occurs
during transmission of certain genetic subtypes and may impact viral RNA
levels. J. Virol. 79:6528–6531.
9. Cooper, C. A., E. Gasteiger, and N. H. Packer. 2001. GlycoMod—a software
tool for determining glycosylation compositions from mass spectrometric
data. Proteomics 1:340–349.
10. Cutalo, J. M., L. J. Deterding, and K. B. Tomer. 2004. Characterization of
glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spec-
trometry. J. Am. Soc. Mass Spectrom. 15:1545–1555.
11. Dalpathado, D. S., and H. Desaire. 2008. Glycopeptide analysis by mass
spectrometry. Analyst 133:731–738.
12. Dalpathado, D. S., et al. 2006. Comparative glycomics of the glycoprotein
follicle stimulating hormone: glycopeptide analysis of isolates from two
mammalian species. Biochemistry 45:8665–8673.
13. Derdeyn, C. A., et al. 2004. Envelope-constrained neutralization-sensitive
HIV-1 after heterosexual transmission. Science 303:2019–2022.
14. Desaire, H., and D. Hua. 2009. When can glycopeptides be assigned based
solely on high-resolution mass spectrometry data? Int. J. Mass Spectrom.
287:21–26.
15. Doores, K. J., et al. 2010. Envelope glycans of immunodeficiency virions are
almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. U. S. A. 107:
13800–13805.
16. Drake, P. M., et al. 2010. Sweetening the pot: adding glycosylation to the
biomarker discovery equation. Clin. Chem. 56:223–236.
17. Geyer, H., C. Holschbach, G. Hunsmann, and J. Schneider. 1988. Carbohy-
drates of human immunodeficiency virus. Structures of oligosaccharides
linked to the envelope glycoprotein 120. J. Biol. Chem. 263:11760–11767.
18. Geyer, H., and R. Geyer. 2006. Strategies for analysis of glycoprotein glyco-
sylation. Biochim. Biophys. Acta 1764:1853–1869.
19. Go, E. P., et al. 2009. Glycosylation site-specific analysis of clade C HIV-1
envelope proteins. J. Proteome Res. 8:4231–4242.
20. Go, E. P., et al. 2008. Glycosylation site-specific analysis of HIV envelope
proteins (JR-FL and CON-S) reveals major differences in glycosylation site
occupancy, glycoform profiles, and antigenic epitopes’ accessibility. J. Pro-
teome Res. 7:1660–1674.
21. Go, E. P., et al. 2007. GlycoPep DB: a tool for glycopeptide analysis using a
“Smart Search.” Anal. Chem. 79:1708–1713.
22. Go, E. P., et al. Methods development for analysis of partially deglycosylated
proteins and application to an HIV envelope protein vaccine candidate. Int.
J. Mass Spectrom., in press.
23. Hagglund, P., J. Bunkenborg, F. Elortza, O. N. Jensen, and P. Roepstorff.
2004. A new strategy for identification of N-glycosylated proteins and un-
ambiguous assignment of their glycosylation sites using HILIC enrichment
and partial deglycosylation. J. Proteome Res. 3:556–566.
24. Hagglund, P., et al. 2007. An enzymatic deglycosylation scheme enabling
identification of core fucosylated N-glycans and O-glycosylation site mapping
of human plasma proteins. J. Proteome Res. 6:3021–3031.
25. Han, J. C., and G. Y. Han. 1994. A procedure for quantitative determination
of Tris(2-carboxyethyl)phosphine, an odorless reducing agent more stable
and effective than dithiothreitol. Anal. Biochem. 220:5–10.
26. Hirabayashi, J. 2004. Lectin-based structural glycomics: glycoproteomics
and glycan profiling. Glycoconj. J. 21:35–40.
27. Ihaka, R., and R. Gentleman. 1996. R: a language for data analysis and
graphics. J. Comput. Graph. Stat. 5:299–314.
28. Irungu, J., E. P. Go, D. S. Dalpathado, and H. Desaire. 2007. Simplification
of mass spectral analysis of acidic glycopeptides using GlycoPep ID. Anal.
Chem. 79:3065–3074.
29. Irungu, J., et al. 2008. Comparison of HPLC/ESI-FTICR MS versus
MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated
HIV envelope glycoprotein. J. Am. Soc. Mass Spectrom. 19:1209–1220.
30. Jones, J., S. S. Krag, and M. J. Betenbaugh. 2005. Controlling N-linked
glycan site occupancy. Biochim. Biophys. Acta 1726:121–137.
31. Jung, K. Y., W. R. Cho, and F. E. Regnier. 2009. Glycoproteomics of plasma
based on narrow selectivity lectin affinity chromatography. J. Proteome Res.
8:643–650.
32. Keele, B. F., and C. A. Derdeyn. 2009. Genetic and antigenic features of the
transmitted virus. Curr. Opin. HIV AIDS 4:352–357.
33. Keele, B. F., et al. 2008. Identification and characterization of transmitted
and early founder virus envelopes in primary HIV-1 infection. Proc. Natl.
Acad. Sci. U. S. A. 105:7552–7557.
34. Kong, L., et al. 2010. Expression-system-dependent modulation of HIV-1
envelope glycoprotein antigenicity and immunogenicity. J. Mol. Biol. 403:
131–147.
35. Kornfeld, R., and S. Kornfeld. 1985. Assembly of asparagine-linked oligo-
saccharides. Annu. Rev. Biochem. 54:631–664.
36. Kraft, Z., et al. 2008. Characterization of neutralizing antibody responses
elicited by clade A envelope immunogens derived from early transmitted
viruses. J. Virol. 82:5912–5921.
37. Larkin, M. A., et al. 2007. Clustal W and Clustal X version 2.0. Bioinfor-
matics 23:2947–2948.
VOL. 85, 2011 GLYCOSYLATION OF HIV-1 TRANSMITTED/FOUNDER ENVELOPES 8283
 on S
eptem
ber 10, 2014 by U
niversity of K
ansas
http://jvi.asm
.org/
D
ow
nloaded from
 
38. Learn, G. H., et al. 2002. Virus population homogenization following acute
human immunodeficiency virus type 1 infection. J. Virol. 76:11953–11959.
39. Leonard, C. K., et al. 1990. Assignment of intrachain disulfide bonds and
characterization of potential glycosylation sites of the type 1 recombinant
human immunodeficiency virus envelope glycoprotein (gp120) expressed in
Chinese hamster ovary cells. J. Biol. Chem. 265:10373–10382.
40. Li, M., et al. 2006. Genetic and neutralization properties of subtype C human
immunodeficiency virus type 1 molecular env clones from acute and early
heterosexually acquired infections in southern Africa. J. Virol. 80:11776–
11790.
41. Liao, H. X., et al. 2006. A group M consensus envelope glycoprotein induces
antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.
Virology 353:268–282.
42. Liu, Y., et al. 2008. Env length and N-linked glycosylation following trans-
mission of human immunodeficiency virus type 1 subtype B viruses. Virology
374:229–233.
43. Maley, F., R. B. Trimble, A. L. Tarentino, and T. H. Plummer, Jr. 1989.
Characterization of glycoproteins and their associated oligosaccharides
through the use of endoglycosidases. Anal. Biochem. 180:195–204.
44. Medzihradszky, K. F. 2005. Characterization of protein N-glycosylation.
Methods Enzymol. 405:116–138.
45. Mizuochi, T., et al. 1990. Diversity of oligosaccharide structures on the
envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the
lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with
bisecting N-acetylglucosamine residues. J. Biol. Chem. 265:8519–8524.
46. Mizuochi, T., et al. 1988. Carbohydrate structures of the human-immuno-
deficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced
in Chinese-hamster ovary cells. Biochem. J. 254:599–603.
47. Morelle, W., K. Canis, F. Chirat, V. Faid, and J. C. Michalski. 2006. The use
of mass spectrometry for the proteomic analysis of glycosylation. Proteomics
6:3993–4015.
48. Morelle, W., and J. C. Michalski. 2007. Analysis of protein glycosylation by
mass spectrometry. Nat. Protoc. 2:1585–1602.
49. Nawaz, F., et al. 2011. The genotype of early-transmitting HIV gp120s
promotes alphabeta-reactivity, revealing alphabetaCD4
 T cells as key tar-
gets in mucosal transmission. PLoS Pathog. 7:e1001301.
50. Nicoli, R., et al. 2010. Advances in LC platforms for drug discovery. Expert
Opin. Drug Discov. 5:475–489.
51. North, S. J., P. G. Hitchen, S. M. Haslam, and A. Dell. 2009. Mass spec-
trometry in the analysis of N-linked and O-linked glycans. Curr. Opin. Struct.
Biol. 19:498–506.
52. Paulson, J. C., and K. J. Colley. 1989. Glycosyltransferases. Structure, local-
ization, and control of cell type-specific glycosylation. J. Biol. Chem. 264:
17615–17618.
53. Paulson, J. C. 1989. Glycoproteins: what are the sugar chains for? Trends
Biochem.Sci. 14:272–276.
54. Qiu, R. Q., and F. E. Regnier. 2005. Use of multidimensional lectin affinity
chromatography in differential glycoproteomics. Anal. Chem. 77:2802–2809.
55. Rademeyer, C., et al. 2007. Genetic characteristics of HIV-1 subtype C
envelopes inducing cross-neutralizing antibodies. Virology 368:172–181.
56. Raska, M., et al. 2010. Glycosylation patterns of HIV-1 gp120 depend on the
type of expressing cells and affect antibody recognition. J. Biol. Chem.
285:20860–20869.
57. Rerks-Ngarm, S., et al. 2009. Vaccination with ALVAC and AIDSVAX to
prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209–2220.
58. Salazar-Gonzalez, J. F., et al. 2009. Genetic identity, biological phenotype,
and evolutionary pathways of transmitted/founder viruses in acute and early
HIV-1 infection J. Exp. Med. 206:1273–1289.
59. Schulz, B. L., and M. Aebi. 2009. Analysis of glycosylation site occupancy
reveals a role for Ost3p and Ost6p in site-specific N-glycosylation efficiency.
Mol. Cell. Proteomics 8:357–364.
60. Segu, Z. M., A. Hussein, M. V. Novotny, and Y. Mechref. 2010. Assigning
N-glycosylation sites of glycoproteins using LC/MSMS in conjunction with
Endo-M/exoglycosidase mixture. J. Proteome Res. 9:3598–3607.
61. Tarentino, A. L., and T. H. Plummer, Jr. 1994. Enzymatic deglycosylation of
asparagine-linked glycans: purification, properties, and specificity of oligo-
saccharide-cleaving enzymes from Flavobacterium meningosepticum. Meth-
ods Enzymol. 230:44–57.
62. Ungar, D. 2009. Golgi linked protein glycosylation and associated diseases.
Semin. Cell Dev. Biol. 20:762–769.
63. Wyss, D. F., et al. 1995. Conformation and function of the N-linked glycan in
the adhesion domain of human CD2. Science 269:1273–1278.
64. Yamaguchi, H. 2002. Chaperone-like functions of N-glycans in the formation
and stabilization of protein conformation. Trends Glycosci. Glycotechnol.
14:139–151.
65. Yeh, J. C., J. R. Seals, C. I. Murphy, H. van Halbeek, and R. D. Cummings.
1993. Site-specific N-glycosylation and oligosaccharide structures of recom-
binant HIV-1 gp120 derived from a baculovirus expression system. Biochem-
istry 32:11087–11099.
66. Zaia, J. 2008. Mass spectrometry and the emerging field of glycomics. Chem.
Biol. 15:881–892.
67. Zhang, M., et al. 2004. Tracking global patterns of N-linked glycosylation site
variation in highly variable viral glycoproteins: HIV, SIV, and HCV enve-
lopes and influenza hemagglutinin. Glycobiology 14:1229–1246.
68. Zhang, Y., E. P. Go, and H. Desaire. 2008. Maximizing coverage of glycosyl-
ation heterogeneity in MALDI-MS analysis of glycoproteins with up to 27
glycosylation sites. Anal. Chem. 80:3144–3158.
69. Zhu, X., C. Borchers, R. J. Bienstock, and K. B. Tomer. 2000. Mass spec-
trometric characterization of the glycosylation pattern of HIV-gp120 ex-
pressed in CHO cells. Biochemistry 39:11194–11204.
8284 GO ET AL. J. VIROL.
 on S
eptem
ber 10, 2014 by U
niversity of K
ansas
http://jvi.asm
.org/
D
ow
nloaded from
 
